Hemostatic alterations in inflammatory bowel disease: response to therapy

Area of Science:

• Gastroenterology
• Hematology
• Internal Medicine

Background:

• Inflammatory bowel disease (IBD) is associated with various systemic complications.
• Coagulation and platelet function in active IBD require further elucidation.

Purpose of the Study:

• To prospectively investigate coagulation and platelet function in patients with acute, untreated inflammatory bowel disease.
• To assess the correlation between hematological abnormalities and disease activity during treatment.

Main Methods:

• Prospective follow-up of twelve patients with acute, untreated inflammatory bowel disease (IBD).
• Assessment of coagulation factors (fibrinogen, factor V, factor VIII, antithrombin III) and platelet parameters (count, aggregation).
• Monitoring of clinical disease activity and sedimentation rate during therapy.

Main Results:

• All patients exhibited coagulation or platelet abnormalities, despite no symptomatic coagulopathy.
• Common findings included elevated fibrinogen, factor V, factor VIII, and thrombocytosis.
• Depressed antithrombin III levels and abnormal platelet aggregation were also frequently observed.
• During therapy, these hematological abnormalities normalized in correlation with decreased disease activity.

Conclusions:

• Acute, untreated IBD is characterized by widespread, subclinical coagulation and platelet dysfunction.
• These hematological abnormalities are reversible and directly linked to treatment response and reduced inflammation.